PROCEPT BioRobotics (PRCT) Projected to Post Quarterly Earnings on Tuesday

PROCEPT BioRobotics (NASDAQ:PRCT) is expected to be releasing its earnings data after the market closes on Tuesday, February 25th. Analysts expect PROCEPT BioRobotics to post earnings of ($0.34) per share and revenue of $66.79 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

PROCEPT BioRobotics Trading Down 4.8 %

PRCT opened at $62.25 on Friday. The firm has a market cap of $3.25 billion, a price-to-earnings ratio of -31.92 and a beta of 1.03. PROCEPT BioRobotics has a 52 week low of $45.20 and a 52 week high of $103.81. The business’s 50 day moving average is $76.53 and its two-hundred day moving average is $79.85. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

Insider Buying and Selling

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 26,423 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the sale, the chief executive officer now owns 152,762 shares of the company’s stock, valued at approximately $14,851,521.64. This represents a 14.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Alaleh Nouri sold 28,092 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the sale, the executive vice president now directly owns 52,472 shares in the company, valued at $5,096,605.36. This trade represents a 34.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 80,935 shares of company stock valued at $7,882,089 over the last quarter. Company insiders own 17.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on PRCT. Jefferies Financial Group began coverage on PROCEPT BioRobotics in a research report on Thursday, November 14th. They set a “hold” rating and a $95.00 price target on the stock. Wells Fargo & Company reiterated an “overweight” rating and issued a $112.00 target price on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. Morgan Stanley began coverage on PROCEPT BioRobotics in a research note on Monday, December 2nd. They issued an “overweight” rating and a $105.00 target price on the stock. Finally, Truist Financial reiterated a “buy” rating and issued a $105.00 target price (up from $95.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $97.86.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).